Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort

Sarah Westwood; Alison L. Baird; Sneha N. Anand; Alejo J. Nevado-Holgado; Andrey Kormilitzin; Liu Shi; Abdul Hye; Nicholas J. Ashton; Angharad R. Morgan; Isabelle Bos; Stephanie J.B. Vos; Susan Baker; Noel J. Buckley; Mara Ten Kate; Philip Scheltens; Charlotte E. Teunissen; Rik Vandenberghe; Silvy Gabel; Karen Meersmans; Sebastiaan Engelborghs; Ellen E. De Roeck; Kristel Sleegers; Giovanni B. Frisoni; Olivier Blin; Jill C. Richardson; Régis Bordet; José L. Molinuevo; Lorena Rami; Anders Wallin; Petronella Kettunen; Magda Tsolaki; Frans Verhey; Alberto Lléo; Isabel Sala; Julius Popp; Gwendoline Peyratout; Pablo Martinez-Lage; Mikel Tainta; Peter Johannsen; Yvonne Freund-Levi; Lutz Frölich; Valerija Dobricic; Cristina Legido-Quigley; Lars Bertram; Frederik Barkhof; Henrik Zetterberg; B. Paul Morgan; Johannes Streffer; Pieter Jelle Visser; Simon Lovestone

doi:10.3233/JAD-190434

Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort

Sarah Westwood, Alison L. Baird, Sneha N. Anand, Alejo J. Nevado-Holgado, Andrey Kormilitzin, Liu Shi, Abdul Hye, Nicholas J. Ashton, Angharad R. Morgan, Isabelle Bos, Stephanie J.B. Vos, Susan Baker, Noel J. Buckley, Mara Ten Kate, Philip Scheltens, Charlotte E. Teunissen, Rik Vandenberghe, Silvy Gabel, Karen Meersmans, Sebastiaan EngelborghsEllen E. De Roeck, Kristel Sleegers, Giovanni B. Frisoni, Olivier Blin, Jill C. Richardson, Régis Bordet, José L. Molinuevo, Lorena Rami, Anders Wallin, Petronella Kettunen, Magda Tsolaki, Frans Verhey, Alberto Lléo, Isabel Sala, Julius Popp, Gwendoline Peyratout, Pablo Martinez-Lage, Mikel Tainta, Peter Johannsen, Yvonne Freund-Levi, Lutz Frölich, Valerija Dobricic, Cristina Legido-Quigley, Lars Bertram, Frederik Barkhof, Henrik Zetterberg, B. Paul Morgan, Johannes Streffer, Pieter Jelle Visser, Simon Lovestone^*

^*Korrespondierende/r Autor/-in für diese Arbeit

Institut für Neurogenetik

21 Zitate (Scopus)

Abstract

We have previously investigated, discovered, and replicated plasma protein biomarkers for use to triage potential trials participants for PET or cerebrospinal fluid measures of Alzheimer's disease (AD) pathology. This study sought to undertake validation of these candidate plasma biomarkers in a large, multi-center sample collection. Targeted plasma analyses of 34 proteins with prior evidence for prediction of in vivo pathology were conducted in up to 1,000 samples from cognitively healthy elderly individuals, people with mild cognitive impairment, and in patients with AD-type dementia, selected from the EMIF-AD catalogue. Proteins were measured using Luminex xMAP, ELISA, and Meso Scale Discovery assays. Seven proteins replicated in their ability to predict in vivo amyloid pathology. These proteins form a biomarker panel that, along with age, could significantly discriminate between individuals with high and low amyloid pathology with an area under the curve of 0.74. The performance of this biomarker panel remained consistent when tested in apolipoprotein E ϵ4 non-carrier individuals only. This blood-based panel is biologically relevant, measurable using practical immunocapture arrays, and could significantly reduce the cost incurred to clinical trials through screen failure.

Originalsprache	Englisch
Zeitschrift	Journal of Alzheimer's Disease
Jahrgang	74
Ausgabenummer	1
Seiten (von - bis)	213-225
Seitenumfang	13
ISSN	1387-2877
DOIs	https://doi.org/10.3233/JAD-190434
Publikationsstatus	Veröffentlicht - 10.03.2020

Fördermittel

This research was conducted as part of the EMIF-AD project which has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement n◦ 115372, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in-kind contribution. ANH and SL were supported by a MRC Mental Health Data Pathfinder award to the University of Oxford, and by the NIHR Oxford Health Biomedical Research Centre (BRC). FB is supported by the NIHR UCLH biomedical research centre. The Lausanne study was funded by a grant from the Swiss National Research Foundation (SNF 320030141179). Cardiff University acknowledge Wellcome Trust support (grant: 104025/Z/14/Z) as part of the research project entitled “Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer’s Disease”. The views expressed are those of the authors and not necessarily those of the MRC, the NHS, the NIHR or the Department of Health.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Querschnittsbereich: Medizinische Genetik

Dokumente

10.3233/JAD-190434

Weitere Links

Link to publication in Scopus

Zitieren

Westwood, S., Baird, A. L., Anand, S. N., Nevado-Holgado, A. J., Kormilitzin, A., Shi, L., Hye, A., Ashton, N. J., Morgan, A. R., Bos, I., Vos, S. J. B., Baker, S., Buckley, N. J., Ten Kate, M., Scheltens, P., Teunissen, C. E., Vandenberghe, R., Gabel, S., Meersmans, K., ... Lovestone, S. (2020). Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort. Journal of Alzheimer's Disease, 74(1), 213-225. https://doi.org/10.3233/JAD-190434

@article{2593ac9d31ed45aa8cafd0ae5b900343,

title = "Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort",

abstract = "We have previously investigated, discovered, and replicated plasma protein biomarkers for use to triage potential trials participants for PET or cerebrospinal fluid measures of Alzheimer's disease (AD) pathology. This study sought to undertake validation of these candidate plasma biomarkers in a large, multi-center sample collection. Targeted plasma analyses of 34 proteins with prior evidence for prediction of in vivo pathology were conducted in up to 1,000 samples from cognitively healthy elderly individuals, people with mild cognitive impairment, and in patients with AD-type dementia, selected from the EMIF-AD catalogue. Proteins were measured using Luminex xMAP, ELISA, and Meso Scale Discovery assays. Seven proteins replicated in their ability to predict in vivo amyloid pathology. These proteins form a biomarker panel that, along with age, could significantly discriminate between individuals with high and low amyloid pathology with an area under the curve of 0.74. The performance of this biomarker panel remained consistent when tested in apolipoprotein E ϵ4 non-carrier individuals only. This blood-based panel is biologically relevant, measurable using practical immunocapture arrays, and could significantly reduce the cost incurred to clinical trials through screen failure.",

author = "Sarah Westwood and Baird, \{Alison L.\} and Anand, \{Sneha N.\} and Nevado-Holgado, \{Alejo J.\} and Andrey Kormilitzin and Liu Shi and Abdul Hye and Ashton, \{Nicholas J.\} and Morgan, \{Angharad R.\} and Isabelle Bos and Vos, \{Stephanie J.B.\} and Susan Baker and Buckley, \{Noel J.\} and \{Ten Kate\}, Mara and Philip Scheltens and Teunissen, \{Charlotte E.\} and Rik Vandenberghe and Silvy Gabel and Karen Meersmans and Sebastiaan Engelborghs and \{De Roeck\}, \{Ellen E.\} and Kristel Sleegers and Frisoni, \{Giovanni B.\} and Olivier Blin and Richardson, \{Jill C.\} and R{\'e}gis Bordet and Molinuevo, \{Jos{\'e} L.\} and Lorena Rami and Anders Wallin and Petronella Kettunen and Magda Tsolaki and Frans Verhey and Alberto Ll{\'e}o and Isabel Sala and Julius Popp and Gwendoline Peyratout and Pablo Martinez-Lage and Mikel Tainta and Peter Johannsen and Yvonne Freund-Levi and Lutz Fr{\"o}lich and Valerija Dobricic and Cristina Legido-Quigley and Lars Bertram and Frederik Barkhof and Henrik Zetterberg and Morgan, \{B. Paul\} and Johannes Streffer and Visser, \{Pieter Jelle\} and Simon Lovestone",

note = "Funding Information: This research was conducted as part of the EMIF-AD project which has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement n◦ 115372, resources of which are composed of financial contribution from the European Union{\textquoteright}s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies{\textquoteright} in-kind contribution. ANH and SL were supported by a MRC Mental Health Data Pathfinder award to the University of Oxford, and by the NIHR Oxford Health Biomedical Research Centre (BRC). FB is supported by the NIHR UCLH biomedical research centre. The Lausanne study was funded by a grant from the Swiss National Research Foundation (SNF 320030141179). Cardiff University acknowledge Wellcome Trust support (grant: 104025/Z/14/Z) as part of the research project entitled “Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer{\textquoteright}s Disease”. The views expressed are those of the authors and not necessarily those of the MRC, the NHS, the NIHR or the Department of Health. Publisher Copyright: {\textcopyright} 2020 - IOS Press and the authors. All rights reserved. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = mar,

day = "10",

doi = "10.3233/JAD-190434",

language = "English",

volume = "74",

pages = "213--225",

journal = "Journal of Alzheimer's Disease",

issn = "1387-2877",

publisher = "SAGE Publications Ltd",

number = "1",

}

Westwood, S, Baird, AL, Anand, SN, Nevado-Holgado, AJ, Kormilitzin, A, Shi, L, Hye, A, Ashton, NJ, Morgan, AR, Bos, I, Vos, SJB, Baker, S, Buckley, NJ, Ten Kate, M, Scheltens, P, Teunissen, CE, Vandenberghe, R, Gabel, S, Meersmans, K, Engelborghs, S, De Roeck, EE, Sleegers, K, Frisoni, GB, Blin, O, Richardson, JC, Bordet, R, Molinuevo, JL, Rami, L, Wallin, A, Kettunen, P, Tsolaki, M, Verhey, F, Lléo, A, Sala, I, Popp, J, Peyratout, G, Martinez-Lage, P, Tainta, M, Johannsen, P, Freund-Levi, Y, Frölich, L, Dobricic, V, Legido-Quigley, C, Bertram, L, Barkhof, F, Zetterberg, H, Morgan, BP, Streffer, J, Visser, PJ & Lovestone, S 2020, 'Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort', Journal of Alzheimer's Disease, Jg. 74, Nr. 1, S. 213-225. https://doi.org/10.3233/JAD-190434

Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort. / Westwood, Sarah; Baird, Alison L.; Anand, Sneha N. et al.
in: Journal of Alzheimer's Disease, Jahrgang 74, Nr. 1, 10.03.2020, S. 213-225.

Publikation: Beiträge in Fachzeitschriften › Zeitschriftenaufsätze › Forschung › Begutachtung

TY - JOUR

T1 - Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort

AU - Westwood, Sarah

AU - Baird, Alison L.

AU - Anand, Sneha N.

AU - Nevado-Holgado, Alejo J.

AU - Kormilitzin, Andrey

AU - Shi, Liu

AU - Hye, Abdul

AU - Ashton, Nicholas J.

AU - Morgan, Angharad R.

AU - Bos, Isabelle

AU - Vos, Stephanie J.B.

AU - Baker, Susan

AU - Buckley, Noel J.

AU - Ten Kate, Mara

AU - Scheltens, Philip

AU - Teunissen, Charlotte E.

AU - Vandenberghe, Rik

AU - Gabel, Silvy

AU - Meersmans, Karen

AU - Engelborghs, Sebastiaan

AU - De Roeck, Ellen E.

AU - Sleegers, Kristel

AU - Frisoni, Giovanni B.

AU - Blin, Olivier

AU - Richardson, Jill C.

AU - Bordet, Régis

AU - Molinuevo, José L.

AU - Rami, Lorena

AU - Wallin, Anders

AU - Kettunen, Petronella

AU - Tsolaki, Magda

AU - Verhey, Frans

AU - Lléo, Alberto

AU - Sala, Isabel

AU - Popp, Julius

AU - Peyratout, Gwendoline

AU - Martinez-Lage, Pablo

AU - Tainta, Mikel

AU - Johannsen, Peter

AU - Freund-Levi, Yvonne

AU - Frölich, Lutz

AU - Dobricic, Valerija

AU - Legido-Quigley, Cristina

AU - Bertram, Lars

AU - Barkhof, Frederik

AU - Zetterberg, Henrik

AU - Morgan, B. Paul

AU - Streffer, Johannes

AU - Visser, Pieter Jelle

AU - Lovestone, Simon

N1 - Funding Information: This research was conducted as part of the EMIF-AD project which has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement n◦ 115372, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in-kind contribution. ANH and SL were supported by a MRC Mental Health Data Pathfinder award to the University of Oxford, and by the NIHR Oxford Health Biomedical Research Centre (BRC). FB is supported by the NIHR UCLH biomedical research centre. The Lausanne study was funded by a grant from the Swiss National Research Foundation (SNF 320030141179). Cardiff University acknowledge Wellcome Trust support (grant: 104025/Z/14/Z) as part of the research project entitled “Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer’s Disease”. The views expressed are those of the authors and not necessarily those of the MRC, the NHS, the NIHR or the Department of Health. Publisher Copyright: © 2020 - IOS Press and the authors. All rights reserved. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/3/10

Y1 - 2020/3/10

N2 - We have previously investigated, discovered, and replicated plasma protein biomarkers for use to triage potential trials participants for PET or cerebrospinal fluid measures of Alzheimer's disease (AD) pathology. This study sought to undertake validation of these candidate plasma biomarkers in a large, multi-center sample collection. Targeted plasma analyses of 34 proteins with prior evidence for prediction of in vivo pathology were conducted in up to 1,000 samples from cognitively healthy elderly individuals, people with mild cognitive impairment, and in patients with AD-type dementia, selected from the EMIF-AD catalogue. Proteins were measured using Luminex xMAP, ELISA, and Meso Scale Discovery assays. Seven proteins replicated in their ability to predict in vivo amyloid pathology. These proteins form a biomarker panel that, along with age, could significantly discriminate between individuals with high and low amyloid pathology with an area under the curve of 0.74. The performance of this biomarker panel remained consistent when tested in apolipoprotein E ϵ4 non-carrier individuals only. This blood-based panel is biologically relevant, measurable using practical immunocapture arrays, and could significantly reduce the cost incurred to clinical trials through screen failure.

AB - We have previously investigated, discovered, and replicated plasma protein biomarkers for use to triage potential trials participants for PET or cerebrospinal fluid measures of Alzheimer's disease (AD) pathology. This study sought to undertake validation of these candidate plasma biomarkers in a large, multi-center sample collection. Targeted plasma analyses of 34 proteins with prior evidence for prediction of in vivo pathology were conducted in up to 1,000 samples from cognitively healthy elderly individuals, people with mild cognitive impairment, and in patients with AD-type dementia, selected from the EMIF-AD catalogue. Proteins were measured using Luminex xMAP, ELISA, and Meso Scale Discovery assays. Seven proteins replicated in their ability to predict in vivo amyloid pathology. These proteins form a biomarker panel that, along with age, could significantly discriminate between individuals with high and low amyloid pathology with an area under the curve of 0.74. The performance of this biomarker panel remained consistent when tested in apolipoprotein E ϵ4 non-carrier individuals only. This blood-based panel is biologically relevant, measurable using practical immunocapture arrays, and could significantly reduce the cost incurred to clinical trials through screen failure.

UR - https://www.scopus.com/pages/publications/85082024715

U2 - 10.3233/JAD-190434

DO - 10.3233/JAD-190434

M3 - Journal articles

C2 - 31985466

AN - SCOPUS:85082024715

SN - 1387-2877

VL - 74

SP - 213

EP - 225

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

IS - 1

ER -

Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort

Abstract

Fördermittel

UN SDGs

Strategische Forschungsbereiche und Zentren

Dokumente

Weitere Links

Fingerprint

Zitieren